Biohaven stock surged early Friday after the FDA canceled an upcoming meeting to discuss the benefits and risks of its drug, ...

On a very good Friday for the stock market, Biohaven 's ( BHVN 6.33%) performance was exceptional. The clinical-stage biotech ...

Biohaven (NYSE:BHVN) shares spiked in the premarket on Friday after the FDA revoked an advisory committee meeting scheduled ...

Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 ...

Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for ...

More bad news has come down for Biohaven’s small molecule troriluzole. | More bad news has come down for Biohaven’s small molecule troriluzole. After the FDA decided to convene an advisory committee ...

--Biohaven Ltd., a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...

Biohaven reported that its novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, demonstrated encouraging preliminary clinical activity ...

Biohaven Pharmaceutical Holding Company Ltd., parent company of Biohaven Therapeutics, is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to ...

A Biohaven Pharmaceuticals drug developed to treat disease by modulating a neurotransmitter that’s important to normal brain function has failed a pivotal study in a rare neuromuscular disorder ...